MoonLake Immunotherapeutics (MLTX) Preferred Stock Liabilities (2020 - 2021)

MoonLake Immunotherapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $115.0 million for Q4 2021.

• In Q4 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $115.0 million; the TTM figure through Dec 2021 stood at $115.0 million (changed 0.0% YoY), while the FY2021 annual figure was $115.0 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was $115.0 million for Q4 2021 at MoonLake Immunotherapeutics, roughly flat from $115.0 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $115.0 million in Q4 2020 to a low of $107.3 million in Q2 2021.